Adverum Biotechnologies, Inc.
Clinical trials sponsored by Adverum Biotechnologies, Inc., explained in plain language.
-
Gene therapy for wet AMD: how do eyes hold up years later?
Disease control OngoingThis study follows 23 people who received a single dose of ADVM-022 gene therapy for wet age-related macular degeneration (AMD). Researchers are checking long-term safety and whether vision improvements last. Participants are observed over time without receiving additional treatm…
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 26, 2026 10:14 UTC
-
One shot could replace dozens: gene therapy trial for blinding eye disease
Disease control OngoingThis Phase 3 study tests a single injection of a gene therapy called Ixo-vec in 311 people with wet age-related macular degeneration, a leading cause of vision loss. The goal is to see if one treatment can control the disease as well as or better than current standard-of-care eye…
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 26, 2026 10:08 UTC